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Abstract
Background: Several enzyme-linked immunosorbent assay (ELISA)-kits are commercially available
for the rapid diagnosis of dengue infection, and have demonstrated good sensitivity and specificity
in paired serum samples. In practice, however, often only one blood sample is available from febrile
travellers returning from dengue endemic areas.
Methods: To evaluate the diagnostic value of positive dengue antibody-titres performed by a
standard ELISA (PanBio IgM- and IgG-ELISA) in single serum samples (regarded as "probable
infection"), 127 positive samples were further analyzed using envelope/membrane IgM-, and
nonstructural protein 1 IgM- and IgG-ELISAs, immunofluorescence assays, and real-time reverse
transcription polymerase chain reaction assays (RT-PCR). A combination of the test-results served
as the diagnostic "gold standard". A total of 1,035 febrile travellers returning from dengue-endemic
countries with negative dengue-serology and RT-PCR served as controls to compare clinical and
haematological features.
Results: Overall, only 64 (positive predictive value = 50%) of the probable cases were confirmed
by additional analysis and 54 (42.5%) were confirmed to be "false-positive". Rash was the only
clinical feature significantly associated with confirmed dengue fever. The combination of
thrombocytopenia and leucopenia was present in 40.4% of confirmed and in 6.1% of false-positive
cases. Thus, the positive predictive value for the combination of positive PanBio-ELISA plus the two
haematological features was 90.5%.
Conclusion:  The examination of paired serum samples is considered the most reliable
serodiagnostic procedure for dengue. However, if only one blood sample is available, a single
positive ELISA-result carries a high rate of false-positivity and should be confirmed using a second
and more specific diagnostic technique. In the absence of further testing, platelet and white blood
cell counts are helpful for the correct interpretation.
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Background
The increase in international air travel, and the increasing
transmission of dengue in the tropics mean that health
care providers in western countries are more likely to be
confronted with travel-acquired dengue infections [1].
Worldwide, dengue is nowadays regarded as the most
important arboviral disease of humans and is endemic in
more than 100 tropical and subtropical countries [2].
Clinically, most dengue infections in international travel-
lers present either asymptomatically or as a febrile illness,
often accompanied by headache and severe myalgia [3-5].
Currently three basic diagnostic methods are used in lab-
oratories, including viral isolation, detection of the
genomic sequence by a nucleic acid amplification tech-
nology assay, and detection of virus-specific antibodies
[6]. However, due to labour intensiveness and high costs,
the first and the second method are rarely available even
in specialized travel clinics.
The serological diagnosis of dengue is limited by the fact
that antibodies usually arise in the late stage of the acute
illness. Several studies have demonstrated that only in a
small proportion of infected patients, immunoglobulin M
(IgM) is detectable during the first 3 to 4 days after onset
of symptoms [7,8]. Cross reactivity with several other fla-
viviruses and previous immunizations in travellers against
yellow fever (YF), Japanese encephalitis (JE), and tick-
borne encephalitis may pose additional problems in the
interpretation of the serological results [9]. Thus, the
examination of paired serum samples is considered the
most reliable serodiagnostic procedure with increasing
titres being required to confirm the diagnosis. In contrast,
the detection of dengue IgM-antibodies only indicates
"probable" infection [10].
In clinical practice, however, frequently only a single
serum sample is available from a febrile traveller who
returned from the tropics. In patients seeking medical care
for post-travel illness, malaria needs to be excluded in a
first step as it might be fatal if not treated as soon as pos-
sible. Since dengue is the most common arboviral disease
in man, a second diagnostic step would be the interpreta-
tion of a dengue serological result from the first serum
sample.
Several enzyme-linked immunosorbent assay (ELISA)-kits
including dipstick systems are commercially available for
the rapid diagnoses of dengue virus infection and demon-
strated good sensitivity and specificity in paired serum
samples [11-13]. However, most of those tests have been
evaluated with paired sera of patients living in endemic
area, most often in Asia. For these reasons, a study has
been performed to evaluate the diagnostic value of a pos-
itive single specimen test result revealed by a standard
ELISA-kit (PanBio-IgM- and IgG-ELISA) in ill travellers
returning from dengue endemic countries in different
parts of the world and how to increase its predictive value
with the help of simple clinical and haematological fea-
tures. Data regarding the geographical risk and the devel-
opment of dengue antibody-prevalence over the study-
period have been published elsewhere [14].
Methods
Sampling
Blood samples were collected at the Berlin Institute of
Tropical Medicine, Germany. Approximately 5,000
patients annually seek medical assistance post travel at the
outpatient department (OPD) of the institute. Before con-
sultation each patient is asked to fill out a questionnaire
to provide information on major complaints, travel desti-
nation, travel duration, risk behaviour and preventive
measures before and during the journey.
Patients were included in this study who presented during
the time periods 1996 to 1998 and 2002 to 2004 at the
OPD with onset of fever during travel in dengue endemic
areas or up to 12 days post return. Available banked sera,
initially obtained for diagnostic purposes, were retrospec-
tively investigated for acute or recent dengue infection. To
compare patients with and without dengue infection and
to take into account "non-febrile" presentations of the
infection, clinical and laboratory data of travellers return-
ing from same destinations but with complaints other
than fever were collected. For convenience, patients were
included in this group who were suffering from non-
febrile diarrhoea. All data were retrieved from the patients'
medical charts and the above mentioned questionnaires.
The research has been conducted in accordance to the
Central Ethics Committee of the German Federal Medical
Association and in compliance with the Helsinki Declara-
tion.
Laboratory testing
Screening tests
All serum samples of included patients were screened for
dengue antibodies by using both a commercially available
IgM-capture ELISA and an IgG indirect ELISA (PanBio Pty
Ltd., East Brisbane, Australia). A probable acute infection
was defined according to the manufacturer's instruction as
having a sample:calibrator absorbance ratio of IgM ≥ 1.0
(defined as a titre of ≥ 10 U) and/or (characterizing sec-
ondary infections) of IgG ≥ 4.0 (defined as a titre of ≥ 40
U).
Confirmation of positive screening test results
As outlined in figure 1, all serum samples with positive
ELISA results were further investigated to confirm the
diagnosis by using envelope/membrane (E/M) and non-
structural protein (NS) 1 serotype-specific capture IgMBMC Infectious Diseases 2006, 6:120 http://www.biomedcentral.com/1471-2334/6/120
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ELISAs and a NS1 serotype-specific IgG ELISA as previ-
ously described: Briefly, for the E/M serotype-specific cap-
ture IgM ELISA, microliter wells were incubated with 100
µL of a cocktail containing 1 µg of monoclonal antibody
D56-3 per mL and diluted culture supernatant of DEN-1,
DEN-2, DEN-3, DEN-4, or JE virus-infected Vero cells
[15]. The assay of NS1 serotype-specific capture IgM ELISA
is similar to that of E/M serotype-specific capture IgM
ELISA with two differences: Monoclonal antibody D2/8-1
was used in the NS1 capture IgM ELISA, and patient serum
samples were used at a 1:20 dilution. The wells for the
NS1 serotype-specific IgG ELISA were incubated with 1:3-
diluted NS1-containing culture supernatants of DEN-1,
DEN-2, DEN-3, DEN-4, or JE virus-infected Vero cells in
PBST-1% BSA-5% normal rabbit serum [16]. Further-
more, an additional testing was performed by an immun-
ofluorescence assay (IFA) (Euroimmun AG, Luebeck,
Germany).
By definition, a screening test result was classified as "true
positive" if the combined analysis of all four tests was pos-
itive. If the results of these four confirmatory antibody
tests were discrepant, sera collected during the acute phase
of illness were processed using real-time reverse transcrip-
tion polymerase chain reaction assays (RT-PCR) for the
detection of viral nucleic acid as described elsewhere [17]
combined with virus isolation in cell culture. A positive
RT-PCR or virus isolation confirmed the dengue infection,
regardless of discrepant confirmatory tests. Discrepant
confirmatory test results in combination with a positive
screening test were classified as "not interpretable", also if
RT-PCR or virus isolation were negative.
Analysis of negative screening test results
If sera tested negative with the initial PanBio-ELISA, all
blood samples that were collected during the acute phase
of illness (i.e. time from onset of illness until blood col-
Laboratory tests performed within the study population Figure 1
Laboratory tests performed within the study population. IFA = immunofluorescence assay. JEV = Japanese encephalitis 
virus. NS1 = non-structural protein 1. E/M = envelope/membrane. RT-PCR = real-time reverse transcription polymerase chain 
reaction.
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lection less than 8 days) were further investigated by using
RT-PCR. For this purpose, included sera were processed in
pools of 5 samples. In a second step, each sample of a pos-
itive pool was individually tested by RT-PCR.
Haematological parameter
Leucopenia was defined as a white cell blood count below
or equal to 4/nL and thrombocytopenia was defined as a
thrombocyte count below or equal to 150/nL.
Statistical methods
All data were entered into a Microsoft Access database
(Microsoft Access 2002, Microsoft Corp., Redmond, WA)
and exported to SPSS (version 13.0 for Windows; SPSS
Inc., Chicago, IL) for statistical analyses. Descriptive statis-
tics were used to describe the frequencies of patients'
symptoms and the laboratory investigations. Odds ratios
and 95% confidence intervals (CI) were determined for
the comparisons of clinical and laboratory features of
travellers with and without dengue infections. As the hae-
matological and serological data were not normally dis-
tributed, the median values were calculated, and when
comparing two independent variables the Mann-Whitney
rank sum test was used. A statistically significant differ-
ence was determined by a p-value <0.05.
Results
A total 2,259 patients with a median age of 33 years (range
2 – 79) were eligible to be included in the study. Of these
1,163 were male and 1,096 were female. Reasons for pre-
senting at the OPD were either travel-associated fever (n =
1,091) or diarrhoea without fever (n = 1,168). The
patients were classified according to the time of blood col-
lection with 35% presenting 1 to 3 days, 20% presenting
4 to 6 days, 12% presenting 7 to 9 days, and 33% present-
ing 10 days or later after the onset of symptoms. A total of
1,020 patients had recently returned from Asia (n = 514
with fever; n = 506 with diarrhoea), 685 returned from
Africa (n = 345 with fever; n = 340 with diarrhoea), and
550 from South-Central America and the Caribbean (n =
230 with fever; n = 320 with diarrhoea). Four patients
travelled to more than one continent during their trip (n
= 2 with fever; n = 2 with diarrhoea).
By screening all patients' sera with the Pan-Bio IgM- and
IgG-ELISAs, results indicated a probable dengue infection
in 127 (5.6%) cases (n = 89 or 8.2% in patients with fever;
n = 38 or 3.3% in patients with diarrhoea). Of these, 10
were positive defined by high IgG-antibody-titres only,
and 4 had both high IgG- and IgM-antibody titres.
As described in the method section, the decision of
whether a screening test result was classified as true posi-
tive or as false positive has been established with the com-
bination of four confirmatory antibody tests (E/M-specific
and NS1 serotype-specific capture IgM ELISAs, NS1 sero-
type-specific IgG ELISA, and IFA). Performed on each of
the 127 samples, the results of these four confirmatory
tests were concordant in 115 samples (61 concordant pos-
itive, and 54 concordant negative), and discrepant in 12
samples. Among these 12 samples with discrepant con-
firmatory antibody tests, three were positive in RT-PCR or
virus isolation. In summary, the additional analysis of the
127 sera of patients with probable dengue infection (i.e.
positive PanBio ELISA) confirmed the disease in 64 (pos-
itive predictive value = 50%). Fifty-four (42.5%) samples
were classified not to be dengue fever (false positive sera).
For 9 (7%) samples results were classified as not interpret-
able due to discrepant results of the confirmatory tests.
The serotyping-results of the confirmed infections have
been published previously [14].
A total of 1,031 PanBio ELISA-negative sera collected dur-
ing the acute phase of illness were further investigated by
RT-PCR. Of these, 5 turned out to be viraemic yielding a
total of 69 confirmed dengue-infections. ELISA-negative
but RT-PCR positive cases were observed only during the
first three days of symptoms but not on day 4 to 7 (Figure
2).
Details of serological results
Of the 10 probable cases with high positive IgG-antibody
levels only, 5 turned out to be true positive and 4 turned
out to be false positive (IgG titres were 44 U, 47 U, 69 U,
and 94 U on day 2, 5, 35, and 36, respectively). In one case
the confirmatory tests were discrepant. All 4 samples with
Test interpretation of combined PanBio-IgG and IgM ELISA Figure 2
Test interpretation of combined PanBio-IgG and IgM 
ELISA. Results are presented according to time of blood 
collection (days after onset of illness). A combination of four 
tests (E/M-specific and NS1 serotype-specific capture IgM 
ELISAs, NS1 serotype-specific IgG ELISA, and IFA) were used 
to classify the PanBio-ELSIA test result as true positive and 
false positive.
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both positive IgG and IgM antibodies in the PanBio ELISA
were classified as true positive in accordance with the four
confirmatory tests.
A higher frequency of false positive PanBio-ELISA results
was observed in the first three days after onset of symp-
toms, and in cases where the blood collection was per-
formed more than 15 days after the onset of symptoms
(Figure 2).
Travelling in Southeast-Asia was associated with a signifi-
cantly lower risk of the PanBio-ELISA showing a false pos-
itive result compared to other destinations (p-value =
0.0001). In patients returning from Sub-Saharan Africa 10
of 15 (67%) samples, returning from the Indian subcon-
tinent 16 of 25 (64%) samples, and returning from Latin-
America and the Caribbean 15 of 27 (55.6%) samples
turned out to be false positive. In contrast, only 13 of 51
(25.5%) samples from patients travelling in Southeast-
Asia had false positive results.
In false positive sera, the median IgM-titre was signifi-
cantly lower than in confirmed cases' sera (13 vs. 29.5 U,
respectively, p < 0.001). However, 8 samples with false
positive results revealed an IgM-titre higher than 20 U
(maximum 70). One serum of a febrile traveller returning
from Thailand (PanBio-ELISA results: IgM 18 U and IgG
negative on day 8 after onset of fever) was found to be
positive for JEV-antibodies (IgM and IgG positive with a
JEV-capture ELISA) which was confirmed by a JEV-specific
NS1 IgG ELISA.
Clinical and laboratory features
Table 1 summarizes the clinical features of 69 travellers
with confirmed dengue infection in comparison to 1,035
febrile travellers without dengue infection. In addition to
fever, main clinical features of dengue were headache
(62%) and muscle pain (50%). When comparing patients
with and without dengue-infection, there was no signifi-
cant difference in the frequencies of major symptoms
except in the occurrence of a skin rash (23.5% vs. 9%,
respectively, p = 0.0001).
A total of 13 patients (19%) with confirmed dengue-virus
infection were afebrile on the day of presentation and
denied a history of recent fever. Of 6 travellers acquiring
dengue in Africa, 4 (66.7%) had no history of fever. This
rate was significantly lower in other geographic regions: 7
of 50 (14%) dengue-patients returning from Asia and 2 of
13 (15%) returning from the Americas and the Caribbean
remained afebrile (p-value 0.01 and 0.046, respectively).
Afebrile dengue-patients stated significantly lower fre-
quencies of headache (23%) and myalgia (15%) (p =
0.001 and 0.004, respectively). Other symptoms among
these patients were nausea (15%), skin rash (8%), and
diarrhoea (100%). However, the latter symptom was used
as an inclusion criterion to recruit afebrile travellers pre-
senting at the OPD. Three of the 13 afebrile dengue
patients also had pathogens identified in their stool sam-
ples (in two cases Giardia lamblia and in one case Shigella).
In the remaining 10 patients, stool examinations were
negative.
Haematological features of dengue included leucopenia
und thrombocytopenia during the acute phase of illness
(53.2% and 48.9%, respectively). The combination of leu-
copenia and thrombocytopenia was present in 40.4% of
the confirmed, in 6.1% of the false positive (OR 10.5;
95% CI 2.1 – 72.0), and in 3.1% of the sero-negative
fever-cases (OR 20.3; 95% CI 9.4 – 43.8). AST was
increased in 5 of 26 (19.2%) dengue cases (4 mildly with
levels not higher than 100 U/L and one patient higher
than 100 U/L), and ALT was increased in 12 of 43 (27.9%)
cases (3 patients with levels higher than 100 U/L). Lactate
dehydrogenase was elevated in 7 of 12 dengue patients
(58.3%) and in 18 of 142 (12.7%) sero-negative fever-
cases (OR 9.6; 95% CI 2.4 – 40.1).
The overall positive predictive value of the PanBio ELISAs
(IgM plus IgG) was 50%. The combination of a positive
PanBio-ELISA result plus the presence of thrombocytope-
nia or plus both leucopenia and thrombocytopenia
increased the positive predictive value of the test to 88.5%
and 90.5%, respectively.
Table 1: Clinical symptoms of studied travellers. Travellers with confirmed dengue virus infection are compared with febrile travellers 
without dengue (negative dengue serology and negative dengue RT-PCR).
Travellers with confirmed dengue 
infection (n = 69)
Febrile travellers without dengue 
(n = 1,035)
OR (95% CI) confirmed vs. fever 
controls
Fever (%) 56/69 (81.2) 1,035/1,035 (100) -
Headache (%) 41/66 (62.1) 460/941 (48.9) 1.7 (1.0–3.0)
Muscle pain (%) 33/66 (50.0) 354/940 (37.7) 1.7 (0.98–2.8)
Diarrhoea (%) 30/69 (43.5) 397/1,035 (38.4) 1.2 (0.7–2.1)
Nausea (%) 15/67 (22.4) 189/944 (20.0) 1.2 (0.6–2.2)
Skin rash (%) 16/68 (23.5) 85/948 (9.0) 3.1 (1.6–5.9)BMC Infectious Diseases 2006, 6:120 http://www.biomedcentral.com/1471-2334/6/120
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Discussion
A total of 2,259 serum samples of travellers returning
from dengue endemic countries were screened for the
prevalence of dengue-antibodies and further analyzed to
evaluate the diagnostic value of positive dengue antibody
titres (IgM and IgG) in single serum samples. Clinical and
haematological parameters of these patients were
included in the analysis for their potential support of the
diagnosis. The study was carried out at a large travel clinic
in Europe, where the spectrum of travel-associated dis-
eases might be suggested to be similar to those of other
clinics in European countries that manage patients for
post-travel illness.
The screening was performed with two commercially
available standard ELISAs (PanBio indirect IgG ELISA and
IgM capture ELISA), which are frequently used in clinical
settings worldwide. The combination of these two tests
showed excellent sensitivity (99–100%) in populations of
endemic countries in Asia [13,18]. Vaughn et al. demon-
strated a high specificity (92%) in paired sera from Thai
patients without flavivirus infection, although 45% of
patients with JE showed elevation of IgG but not IgM [13].
Only few studies have been performed in travellers to
evaluate the specificity and sensitivity of these tests, even
though it might be expected that in this particular popu-
lation other pathogens and previous immunizations cre-
ate a potential problem of cross reactivity, especially if
more specific but also more costly test such as RT-PCR or
plaque reduction neutralization test (PRNT) are not avail-
able. Schwartz et al. were able to demonstrate that among
82 JE and/or YF vaccinated Israeli travellers the IgM test
was negative in all healthy vaccines, and thus highly spe-
cific. The IgG test, however, yielded 11–17% and 15–44%
positives in healthy travellers vaccinated against JE and
YF, respectively [9]. On the other hand, the ELISA kit
detected IgM-antibodies only 4–8 days after the onset of
clinical symptoms, since dengue antibodies tend to rise
late in the acute phase of a primary infection [19]. There-
fore, to increase the sensitivity of an early diagnosis of
dengue, it is highly recommended to perform both den-
gue RT-PCR and dengue E/M-specific capture IgM and IgG
ELISA if available [6,8].
Among 1,031 sero-negative patients presenting in the
acute phase of illness at our travel clinic, five were tested
positive by RT-PCR during the first three days after onset
of symptoms. Of the 21 patients presenting during this
time period with positive PanBio ELISA results, only one
was confirmed by virus isolation but 20 were classified as
false positive (i.e. negative confirmatory antibody tests
and negative RT-PCR/virus isolation). This finding high-
lights that clinicians should consider preferably RT-PCR
to diagnose dengue-infections in patients seeking medical
care up to five days after onset of symptoms, and that
ELISA-results on blood collected during this period of dis-
ease should be used to demonstrate seroconversion or ris-
ing antibody titres in combination with a follow-up
sample but not to confirm the diagnosis with a single
serum sample. However, it must also be pointed out that
a negative RT-PCR test result does not exclude a dengue
infection.
Furthermore, a long time period (> 15 days) between the
onset of the acute symptoms and the blood collection was
also associated with a higher rate of false positive PanBio-
ELISAs. In most of these cases the patients did not have
symptoms at the time of presentation but asked for a
check-up and the identification of a pathogen that might
have caused the fever while travelling.
In our study population, 127 serum samples of travellers
with antibody titres indicating probable acute or recent
dengue infection in the standard PanBio-ELISA were fur-
ther analyzed and revealed a high rate (42.5%) of false
positive results in single specimen analysis. The confirma-
tory analysis has been performed by using an E/M-specific
capture ELISA which has been found to differentiate relia-
bly between JE, YF, dengue, and West Nile virus infection
in previous studies [16]. Furthermore, NS1 isotype- and
serotype-specific IgM and IgG-ELISAs have been applied
that demonstrated a good correlation with dengue virus
PRNT [20]. Overall, it must be concluded that in the
absence of these more specific assays, paired serum are
required to yield the high specificity of the PanBio ELISAs
observed in previous studies [13]. The lacking second
serum sample can be regarded as the major factor for the
low specificity of the assay in our study.
Travelling in South East Asia was significantly associated
with a lower risk to reveal a false positive result in the Pan-
Bio-ELISAs when compared to other travel destinations.
This phenomenon can be explained by the fact that the
positive (and negative) predictive value of a diagnostic
test is influenced by the prevalence of the disease in a spe-
cific geographic region. Regarding dengue virus activity,
Southeast Asia is the most seriously affected area world-
wide [21], and travellers to this region were shown to be
at highest risk when compared to other regions [4,14,22].
The high specificity of the PanBio IgM ELISA in travellers
with previous immunizations demonstrated in a recent
study [9] leads to the suggestion that in our population
other pathogens might have caused cross reactive antibod-
ies in these sick travellers with high but false positive IgM
levels. In one of the investigated patient's sera antibodies
against JEV were detected and were probably responsible
for the false positive result. In 2 of the 54 patients with
false positive dengue ELISA an infection with PlasmodiumBMC Infectious Diseases 2006, 6:120 http://www.biomedcentral.com/1471-2334/6/120
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falciparum was diagnosed, in 5 patients an intestinal infec-
tion with Giardia lamblia, and in one patient with Strongy-
loides stercoralis. However, it might be suggested that none
of these later mentioned pathogens have the potential to
cause cross-reactivities with the PanBio-ELISA. Overall,
possible explanations for false positive PanBio-ELISA
results include cross-reactive flavivirus-specific IgM anti-
bodies, non-specific bindings of IgM antibodies from
other infections, and rheumatoid factor. As mentioned
earlier, a major factor for the low positive predictive value
of the PanBio-ELISA is the fact that only single serum sam-
ples have been tested. This, however, was subject to our
study.
Underlining the good validity of the retrospective analy-
sis, clinical data of the patients are very similar to those
gained prospectively in a population of 465 travellers with
imported dengue infection presenting at 43 European
travel clinics [23] where 63% were reported to have head-
ache, 52% muscle pain, and 34% rash. In our study pop-
ulation, rash was the only clinical symptom significantly
more frequently observed in patients with confirmed den-
gue infection when compared to febrile travellers without
dengue. However, this symptom was present in only 24%
of the patients with dengue infection and was therefore
not helpful to increase the positive predictive value of the
PanBio-ELISA. In contrast, thrombocytopenia was present
in 50% of the dengue patients and supported the correct
diagnosis in combination with the single serum analysis,
but would hardy serve as a single indicator due to the low
prevalence. In a study performed in adults presenting to a
hospital with febrile illnesses in Singapore, rash was iden-
tified as the most reliable clinical parameter to predict
dengue fever [24]. In this population living in a dengue
endemic area, the combination of simple laboratory
parameter (white cell count, haemoglobin, prothrombin
time, creatinine, and bilirubin levels) and rash was dem-
onstrated to potentially predict dengue achieving a sensi-
tivity of 84% and specificity of 85%.
Conclusion
The examination of paired serum samples remains the
most reliable serodiagnostic procedure for dengue. How-
ever, if only one blood sample is available, a single posi-
tive ELISA-result carries a high rate of false-positivity and
should be confirmed using a second and more specific
diagnostic technique. In the absence of further testing,
platelet and white blood cell counts are useful for the cor-
rect interpretation. In our population, the combination of
these two features increased the positive predictive value
of a PanBio-ELISA test from 50% to 90.5%
In the very early stage of illness only RT-PCR or virus iso-
lation can reliably confirm the diagnosis of dengue. Posi-
tive ELISA-results during the first three days of illness
should be mistrusted by the investigator and only be used
as the baseline titre for a second sample. Especially in
cases with only low positive IgM-titres and in the absence
of above described blood count alterations a second
serum sample collected during the convalescent phase is
highly recommended and other potential and treatable
reasons for travel-related fever should be excluded in this
stage. On the other hand, if a single specimen serological
result in combination with the clinical-haematological
findings is highly suggestive for dengue infection, further
expensive investigations could be omitted.
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